Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type i collagen

Journal of Orthopaedic Research

Volumn 29, Issue 1, 2011, Pages 67-73

  Tsai, Wen Chung ^a   Hsu, Chih Chin ^a   Chen, Carl P C ^a   Chang, Hsiang Ning ^a   Wong, Alice M K ^a   Lin, Miao Sui ^a   Pang, Jong Hwei S ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

ciprofloxacin; collagen; matrix metalloproteinase; tendon

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CIPROFLOXACIN; COLLAGEN TYPE 1; GELATIN; GELATINASE A; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACHILLES TENDON; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXPLANT; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TENDINITIS; TENDON; TENDON RUPTURE; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ACHILLES TENDON; ANIMALS; ANTI-INFECTIVE AGENTS; CELL SURVIVAL; CIPROFLOXACIN; COLLAGEN TYPE I; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION;

EID: 78649560907     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21196     Document Type: Article

References (34)

1. Pierfitte C, Royer RJ,. 1996. Tendon disorders with fluoroquinolones. Therapie 51: 419-420.
2. Zabraniecki L, Negrier I, Vergne P, et al. 1996. Fluoroquinolone induced tendinopathy: Reports of 6 cases. J Rheumatol 23: 516-520.
3. Kato M, Takada S, Kashida Y, et al. 1995. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol 23: 385-392.
4. Shakibaei M, Stahlmann R,. 2001. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 75: 97-102.
5. Williams RJ, Attia E, Wickiewicz TL, et al. 2000. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 28: 364-369.
6. Bernard-Beaubois K, Hecquet C, Hayem G, et al. 1998. In vitro study of cytotoxicity of quinolones on rabbit tenocytes. Cell Biol Toxicol 14: 283-292.
7. Corps AN, Harrall RL, Curry VA, et al. 2002. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1β in human tendon-derived cells: A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum 46: 3034-3040.
8. Tsai WC, Hsu CC, Tang FT, et al. 2008. Ciprofloxacin mediated cell proliferation inhibition and G2/M cell cycle arrest in tenocytes. Arthritis Rheum 58: 1657-1663.
9. Tsai WC, Hsu CC, Chen HC, et al. 2009. Ciprofloxacin-mediated inhibition of tenocyte migration and down-regulation of focal adhesion kinase phosphorylation. Eur J Pharmacol 607: 23-26.
10. O'Brien M,. 1992. Functional anatomy and physiology of tendons. Clin Sports Med 11: 505-520.
11. Amiel D, Frank C, Harwood F, et al. 1984. Tendons and ligaments: A morphological and biochemical comparison. J Orthop Res 1: 257-265.
12. Duance VC, Restall DJ, Beard H, et al. 1977. The location of three collagen types in skeletal muscle. FEBS Lett 79: 248-252.
13. Maffulli N, Ewen SW, Waterston SW, et al. 2000. Tenocytes from ruptured and tendinopathic Achilles tendons produce greater quantities of type III collagen than tenocytes from normal Achilles tendons. An in vitro model of human tendon healing. Am J Sports Med 28: 499-505.
14. Jones GC, Corps AN, Pennington CJ, et al. 2006. Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human Achilles tendon. Arthritis Rheum 54: 832-842.
15. Nagase H, Woessner JF, Jr., 1999. Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
16. Aimes RT, Quigley JP,. 1995. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270: 5872-5876.
17. Gomez DE, Alonso DF, Yoshiji H, et al. 1997. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
18. Goupile P, Jayson MIV, Valat J, et al. 1998. Matrix metalloproteinases: The clue to intervertebral disc degeneration? Spine 23: 1612-1626.
19. Alfredson H, Lorentzon M, Backman S, et al. 2003. cDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic Achilles tendinosis. J Orthop Res 21: 970-975.
20. Karousou E, Ronga M, Vigetti D, et al. 2008. Collagens, proteoglycans, MMP-2, MMP-9 and TIMPs in human Achilles tendon rupture. Clin Orthop Relat Res 466: 1577-1582.
21. Tsai WC, Pang JH, Hsu CC, et al. 2006. Ultrasound stimulation of types I and III collagen expression of tendon cell and upregulation of transforming growth factor beta. J Orthop Res 24: 1310-1316.
22. Gotoh M, Hamada K, Yamakawa H, et al. 1997. Significance of granulation tissue in torn supraspinatus insertions: An immunohistochemical study with antibodies against interleukin-1 beta, cathepsin D, and matrix metalloprotease-1. J Orthop Res 15: 33-39.
23. Fu SC, Chan BP, Wang W, et al. 2002. Increased expression of matrix metalloproteinase 1 (MMP1) in 11 patients with patellar tendinosis. Acta Orthop Scand 73: 658-662. (Pubitemid 36020909)
24. Riley GP, Curry V, DeGroot J, et al. 2002. Matrix metalloproteinase activities and their relationship with collagen remodeling in tendon pathology. Matrix Biol 21: 185-195.
25. Lo IK, Marchuk LL, Hollinshead R, et al. 2004. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase mRNA levels are specifically altered in torn rotator cuff tendons. Am J Sports Med 32: 1223-1229.
26. Choi HR, Seiji K, Kazuyoshi H, et al. 2002. Expression and enzymatic activity of MMP-2 during healing process of acute supraspinatus tendon tear in rabbits. J Orthop Res 20: 927-933.
27. Bigg HF, Rowan AD, Barker MD, et al. 2007. Activity of matrix metalloproteinase-9 against native collagen types I and III. FEBS J 274: 1246-1255.
28. Yoshihara Y, Hamada K, Nakajima T, et al. 2001. Biochemical markers in the synovial fluid of glenohumeral joints from patients with rotator cuff tear. J Orthop Res 19: 573-579.
29. Demirag B, Sarisozen B, Ozer O, et al. 2005. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg Am 87: 2401-2410.
30. Kashida Y, Kato M,. 1997. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: Comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother 41: 2389-2393.
31. Bergeron MG,. 1989. The Pharmacokinetics and tissue penetration of the fluoroquinolones. Clin Invest Med 12: 20-22.
32. Dan M, Golomb J, Gorea A, et al. 1986. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother 30: 88-89.
33. MacGown AP, White LO, Brown NM, et al. 1994. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200amg i.v. bd irrespective of renal function. J Antimicrob Chemother 33: 1051-1054.
34. Shah A, Lettieri J, Kaiser L, et al. 1994. Comparative pharmacokinetics and safety of ciprofloxacin 400amg i.v. thrice daily versus 750amg po twice daily. J Antimicrob Chemother 33: 795-801.